Cantor Fitzgerald Reiterates Overweight on Alector
$ALEC
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Cantor Fitzgerald analyst Pete Stavropoulos reiterates Alector (NASDAQ:ALEC) with a Overweight.
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/14/2023 | $8.00 → $15.00 | Hold → Buy | Stifel |
| 12/12/2023 | $12.00 | Buy | Deutsche Bank |
| 9/25/2023 | $4.00 | Sell | Goldman |
| 9/22/2023 | $13.00 | Overweight | Cantor Fitzgerald |
| 1/6/2023 | $24.00 → $12.00 | Buy → Neutral | BofA Securities |
| 9/9/2022 | $27.00 → $13.00 | Overweight → Equal-Weight | Morgan Stanley |
| 7/7/2022 | $15.00 | Buy | Mizuho |
| 4/13/2022 | $9.00 | Sell | Goldman |
Cantor Fitzgerald analyst Pete Stavropoulos reiterates Alector (NASDAQ:ALEC) with a Overweight.
HC Wainwright & Co. analyst Andrew Fein reiterates Alector (NASDAQ:ALEC) with a Buy and maintains $35 price target.
U.S. stock futures were lower this morning, with the Dow futures falling over 50 points on Monday. Shares of Perion Network Ltd. (NASDAQ:PERI) fell sharply in today's pre-market trading after the company lowered its revenue forecast. Perion Network slashed its second-quarter revenue forecast from $118 million – $122 million to $106 million – $108 million. The company lowered its FY24 revenue forecast from $590 million – $610 million to $490 million – $510 million. Perion Network shares dipped 21% to $9.74 in pre-market trading. Here are some big stocks recording losses in today's pre-market trading session. Skye Bioscience, Inc. (NASDAQ:SKYE) shares tumbled 45.2% to $6.00 in
Data from INVOKE-2 Phase 2 clinical trial of AL002 in individuals with early Alzheimer's disease (AD) on track for Q4 2024 Patient baseline characteristics data for the INVOKE-2 trial confirm the intended study population for testing the effects of AL002, a novel TREM2 agonist, in early AD The latozinemab pivotal INFRONT-3 Phase 3 trial continues to progress well, supported by a recent U.S. Food and Drug Administration interaction post Breakthrough Therapy Designation $503.3 million in cash, cash equivalents and investments provide runway through 2026 Management to host conference call and webcast today at 4:30 p.m. ET/1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., Aug. 07, 2024 (GLOBE NEW
SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced it will host a conference call and webcast on Wednesday, August 7, 2024, at 4:30 p.m. ET to discuss results for the second quarter ended June 30, 2024, and provide a mid-year business update. A press release detailing second quarter results will be issued prior to the call. The event will be webcast live under the investor relations section of Alector's website at https://investors.alector.com/events-and-presentations/events, and following the event, a replay will be archived there for 30 days. Interested parties
Data from INVOKE-2, evaluating the most advanced TREM2 candidate in clinical development for early Alzheimer's disease (AD), expected in Q4 2024; trial enrollment completed in Q3 2023 First participant in the global PROGRESS-AD Phase 2 clinical trial of AL101 in early AD dosed in Q1 2024 Latozinemab granted FDA's Breakthrough Therapy Designation for frontotemporal dementia due to a mutation in the progranulin gene (FTD-GRN) Achieved target enrollment in pivotal INFRONT-3 latozinemab Phase 3 trial in FTD-GRN during Q4 2023 $620.0 million in cash, cash equivalents and investments after January 2024 equity offering anticipated to provide runway through 2026 Management to host conference c
Stifel upgraded Alector from Hold to Buy and set a new price target of $15.00 from $8.00 previously
Deutsche Bank initiated coverage of Alector with a rating of Buy and set a new price target of $12.00
Goldman initiated coverage of Alector with a rating of Sell and set a new price target of $4.00
SC 13G/A - Alector, Inc. (0001653087) (Subject)
SC 13G/A - Alector, Inc. (0001653087) (Subject)
SC 13G/A - Alector, Inc. (0001653087) (Subject)
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the Company has entered into a debt financing agreement with Hercules Capital, Inc. (NYSE:HTGC) for up to $50 million. "Alector is in a strong cash position with more than $457 million in cash and investments. This credit facility further enhances our financial strength and provides the Company with increased strategic and operational flexibility," said Marc Grasso, M.D., Chief Financial Officer of Alector. "We anticipate transformational data from both the AL002 INVOKE-2 Phase 2 trial and the latozinemab INFRO
Data from INVOKE-2, evaluating TREM2 agonist candidate AL002 in patients with early Alzheimer's disease (AD), on track for 2024 Participant baseline characteristics in pivotal INFRONT-3 Phase 3 trial suggest a representative study population for testing the effects of latozinemab in frontotemporal dementia with a progranulin gene mutation (FTD-GRN) $457.2 million in cash, cash equivalents and investments provide runway through 2026 SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today reported third quarter 2024 financial results and recent portfolio and business updates. As o
--Participant baseline characteristics in INFRONT-3 suggest a representative study population that enables testing of the effects of latozinemab in frontotemporal dementia with a progranulin gene mutation (FTD-GRN)-- --Latozinemab, a novel investigational human monoclonal antibody, is the most advanced PGRN-elevating candidate in development for the treatment of FTD-GRN-- SOUTH SAN FRANCISCO, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the presentation of a poster on participant baseline characteristics for the pivotal INFRONT-3 Phase 3 clinical trial evaluating the safety and
4 - Alector, Inc. (0001653087) (Issuer)
4 - Alector, Inc. (0001653087) (Issuer)
4 - Alector, Inc. (0001653087) (Issuer)
Data from INVOKE-2, evaluating the most advanced TREM2 candidate in clinical development for early Alzheimer's disease, on track for Q4 2024 Strengthened leadership team with key appointments: Neil Berkley, M.S., M.B.A., named Chief Business Officer; Errol De Souza, Ph.D., and Mark Altmeyer, M.B.A., join Board of Directors $562.1 million in cash, cash equivalents and investments provide runway through 2026 SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today reported first quarter 2024 financial results and recent portfolio and business updates. As of March 31, 202
SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the appointment of Gary Romano, M.D., Ph.D., as Chief Medical Officer. In this role, Dr. Romano will lead the company's global clinical development strategy, including oversight of the clinical development, clinical operations, biometrics and digital science, and medical affairs functions. Dr. Romano will report to Sara Kenkare-Mitra, Ph.D., President and Head of Research and Development of Alector. Dr. Romano's appointment is effective May 23, 2022. "We are delighted to welcome Gary to our executive leadership tea
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering the discovery and development of immuno-neurology therapeutics, today announced the appointment of Marc Grasso, M.D., as Chief Financial Officer (CFO). Dr. Grasso brings extensive biotechnology industry leadership experience, including a successful track record in finance, corporate development and strategic leadership. As Alector's CFO, Dr. Grasso will lead all aspects of the company's financial operations and play a critical role in supporting corporate strategy. Dr. Grasso will report to Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector.
8-K - Alector, Inc. (0001653087) (Filer)
10-Q - Alector, Inc. (0001653087) (Filer)
8-K - Alector, Inc. (0001653087) (Filer)